A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques
Authors:
- Xuan HeXHXuan He
- Abishek ChandrashekarACAbishek Chandrashekar
- Jingyou YuJYJingyou Yu
- Katherine McMahanKMKatherine McMahan
- Frank WegmannFWFrank Wegmann
- Catherine Jacob-DolanCJCatherine Jacob-Dolan
- Jenny S. MaronJMJenny S. Maron
- Caroline AtyeoCACaroline Atyeo
- Huahua WanHWHuahua Wan
- Daniel SellersDSDaniel Sellers
- Jinyan LiuJLJinyan Liu
Open Access
- 30 March 2022
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (638) , eabm4996
Abstract
Ad26.COV2.S has demonstrated durability and clinical efficacy against symptomatic COVID-19 in humans. In this study, we report the correlates of durability of humoral and cellular immune responses in 20 rhesus macaques immunized with single-shot Ad26.COV2.S and the immunogenicity of a booster shot at 8 to 10 months after the initial immunization. Ad26.COV2.S elicited durable binding and neutralizing antibodies as well as memory B cells and long-lived bone marrow plasma cells. Innate immune responses and bone marrow plasma cell responses correlated with durable antibody responses. After Ad26.COV2.S boost immunization, binding and neutralizing antibody responses against multiple SARS-CoV-2 variants increased 31- to 69-fold and 23- to 43-fold, respectively, compared with preboost concentrations. Antigen-specific B cell and T cell responses also increased substantially after the boost immunization. Boosting with a modified Ad26.COV2.S.351 vaccine expressing the SARS-CoV-2 spike protein from the beta variant led to largely comparable responses with slightly higher beta- and omicron-specific humoral immune responses. These data demonstrate that a late boost with Ad26.COV2.S or Ad26.COV2.S.351 resulted in a marked increase in humoral and cellular immune responses that were highly cross-reactive across multiple SARS-CoV-2 variants in rhesus macaques.Keywords
This publication has 34 references indexed in Scilit:
- Circulating T FH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunityScience Translational Medicine, 2018
- CD138 and CD31 Double-Positive Cells Comprise the Functional Antibody-Secreting Plasma Cell Compartment in Primate Bone MarrowFrontiers in Immunology, 2016
- Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems SerologyCell, 2015
- Molecular signatures of antibody responses derived from a systems biology study of five human vaccinesNature Immunology, 2013
- Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)The Journal of Infectious Diseases, 2012
- First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)The Journal of Infectious Diseases, 2012
- Sample-level enrichment analysis unravels shared stress phenotypes among multiple cancer typesGenome Medicine, 2012
- Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and DJournal of Virology, 2007
- Duration of antiviral immunity after smallpox vaccinationNature Medicine, 2003
- Lifetime of plasma cells in the bone marrowNature, 1997